Table of Contents
A lipoprotein(a) test measures Lp(a), an inherited cholesterol particle that standard lipid panels do not detect. Lp(a) levels are largely determined by genetics and stay stable across life, so one measurement is enough for most adults. Roughly one in five people carry an elevated level, and most never learn it.
Heart disease remains the leading cause of death in Florida, at an age-adjusted rate of 135.7 deaths per 100,000 residents in 2024, according to the Florida Department of Health. Lipoprotein(a) accounts for part of that burden in people whose cholesterol panels read normal.
Key Takeaways
- The 2026 ACC/AHA Multisociety Dyslipidemia Guideline, issued March 13, 2026, gives lipoprotein(a) measurement a Class 1 recommendation, meaning every adult should have Lp(a) measured at least once. The 2018 guideline it replaced treated lipoprotein(a) only as a risk-enhancing factor.
- An Lp(a) level at or above 125 nmol/L, or 50 mg/dL, carries roughly 1.4 times the long-term risk of heart attack or stroke, according to the 2026 ACC/AHA guideline. A level at or above 250 nmol/L carries at least twice that risk.
- The LPA gene determines more than 90% of the variation in lipoprotein(a) between individuals, and the driver is the number of KIV-2 repeats a person inherits. Fewer repeats produce higher circulating levels.
- Elevated lipoprotein(a) drives myocardial infarction, ischemic stroke, peripheral artery disease and calcific aortic valve stenosis. Kamstrup, Tybjærg-Hansen and Nordestgaard established the aortic valve link in the Journal of the American College of Cardiology in 2014.
- Novartis announced on September 4, 2026 that pelacarsen lowered lipoprotein(a) but missed its primary cardiovascular endpoint in the phase 3 Lp(a)HORIZON trial. No therapy targeting lipoprotein(a) is approved.
What is lipoprotein(a)?
Lipoprotein(a) is an LDL-like particle whose apolipoprotein B-100 core is covalently bound to apolipoprotein(a), a glycoprotein encoded by the LPA gene. That second protein separates lipoprotein(a) from ordinary LDL cholesterol. Norwegian physician Kåre Berg described lipoprotein(a) in 1963 as the Lp serum system, more than fifty years before guidelines recommended measuring it.
Lipoprotein(a) drives arterial disease through three distinct mechanisms. Lipoprotein(a) delivers cholesterol into the artery wall the way LDL does. Lipoprotein(a) carries oxidized phospholipids, which ignite inflammation inside the plaque. Apolipoprotein(a) shares structural homology with plasminogen, the enzyme precursor that dissolves clots, and that resemblance blocks normal clot breakdown. Duarte Lau and Giugliano documented all three pathways in their 2022 JAMA Cardiology review.
People describe lipoprotein(a) as the sticky kind of cholesterol that runs in the family, and that description tracks the biology closely.
How is lipoprotein(a) different from LDL cholesterol?
Lipoprotein(a) differs from LDL cholesterol in one structural feature and one clinical consequence. The structural feature is the apolipoprotein(a) tail, which LDL particles lack entirely. The clinical consequence follows from it: statins reduce LDL cholesterol by 30% to 55% and leave lipoprotein(a) unchanged. A person lowers LDL cholesterol with diet, exercise and medication. That same person carries the identical lipoprotein(a) level afterward.
What causes high lipoprotein(a)?
The LPA gene determines more than 90% of the variation in lipoprotein(a) between individuals. Diet, body weight, exercise and alcohol intake contribute almost nothing. This makes lipoprotein(a) unlike every other number on a lipid panel, and it explains why the result holds steady across decades.
The specific driver inside the LPA gene is a repeated stretch of DNA called kringle IV type 2, or KIV-2. Copy number ranges from roughly 1 to more than 40 per allele. Fewer KIV-2 repeats produce a smaller apolipoprotein(a) isoform, the liver secretes that smaller isoform more efficiently, and circulating lipoprotein(a) rises as a result. The relationship runs inversely: small isoform, high level. Marlys Koschinsky and Florian Kronenberg established much of this structure-function work.
LPA allele frequencies differ across populations, so median lipoprotein(a) concentrations differ across ancestry groups as well. For patients tracing inherited risk more broadly, Functional DNA Testing and Biological Age Testing examine separate genetic and cellular questions.
What medical conditions raise lipoprotein(a)?
Four medical conditions raise lipoprotein(a) above a person’s genetic setpoint: chronic kidney disease, nephrotic syndrome, hypothyroidism and menopause.
- Chronic kidney disease raises lipoprotein(a) by slowing clearance of the particle from circulation, and the effect grows as filtration rate falls.
- Nephrotic syndrome raises lipoprotein(a) sharply, because heavy urinary protein loss triggers compensatory hepatic lipoprotein production.
- Hypothyroidism raises lipoprotein(a) through reduced hepatic receptor activity, and thyroid hormone replacement reverses the rise.
- Menopause raises lipoprotein(a) modestly in some women, following the decline in circulating estrogen.
None of these four conditions changes the underlying LPA genotype. Each shifts the measured value temporarily, which matters when interpreting a result drawn during active illness.
What is the lipoprotein(a) test?
The lipoprotein(a) test is a single blood draw that measures the concentration of Lp(a) particles in circulation, reported in nmol/L or mg/dL. The draw requires no fasting and takes the same few minutes as any venous sample. One lifetime measurement answers the question for most adults.
On March 13, 2026, the American College of Cardiology and the American Heart Association issued the 2026 Multisociety Guideline on the Management of Dyslipidemia, which replaced the 2018 blood cholesterol guideline. The 2026 guideline gives lipoprotein(a) measurement a Class 1 recommendation, meaning every adult should have lipoprotein(a) measured at least once. The 2018 guideline listed lipoprotein(a) only as a risk-enhancing factor.
That upgrade moved the Lp(a) test, also ordered as an LPA blood test, from specialist use into routine preventive care.
Who should get a lipoprotein(a) test?
Every adult qualifies for one lipoprotein(a) test under the 2026 guideline, and five groups carry higher priority for testing sooner.
- Adults with a family history of premature heart disease, defined as a cardiac event before age 55 in men or 65 in women, carry the highest pretest probability.
- Adults with established atherosclerotic cardiovascular disease need the result to explain residual risk that persists after LDL cholesterol reaches goal.
- Adults with familial hypercholesterolemia carry double inherited risk, because elevated lipoprotein(a) and familial hypercholesterolemia compound each other.
- Adults with calcific aortic valve stenosis need the result because lipoprotein(a) drives valve calcification directly.
- First-degree relatives of anyone with a confirmed high result warrant cascade screening, since each first-degree relative carries a 50% chance of inheriting the same LPA allele.
Why don’t standard lipid panels include lipoprotein(a)?
Standard lipid panels measure four values, and lipoprotein(a) is not one of them. A standard panel reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Lipoprotein(a) requires a separate assay ordered as a separate test.
Two forces kept lipoprotein(a) off the panel for decades. No approved therapy existed to lower it, which removed the incentive to measure it, and assays lacked global standardization, so results moved between laboratories. Both conditions have changed.
The 2026 guideline directs intensified LDL cholesterol lowering in anyone with elevated lipoprotein(a), and nmol/L reporting has largely resolved the assay problem. Ordering lipoprotein(a) now falls to the patient or the physician requesting it specifically, which is where Advanced Bloodwork differs from an annual physical draw.
What is a normal lipoprotein(a) level?
A normal lipoprotein(a) level sits below 75 nmol/L, or below 30 mg/dL. The 2026 ACC/AHA guideline sets the risk-enhancing threshold at 125 nmol/L or 50 mg/dL, a level carrying roughly 1.4-fold increased long-term risk of heart attack or stroke. A level of 250 nmol/L or higher carries at least twofold increased long-term risk. The 2025 focused update of the ESC/EAS dyslipidaemia guidelines uses the same 50 mg/dL cut-point.
The table below maps each band to its clinical meaning.
| Category | nmol/L | mg/dL | What the result means |
|---|---|---|---|
| Optimal | Below 75 | Below 30 | Lipoprotein(a) adds no measurable cardiovascular risk |
| Borderline | 75 to 125 | 30 to 50 | Intermediate zone, interpreted alongside blood pressure, LDL cholesterol and family history |
| High | 125 or above | 50 or above | Risk-enhancing, about 1.4-fold increased long-term risk of heart attack or stroke |
| Very high | 250 or above | 100 or above | At least twofold increased long-term risk, and the level most cardiologists call dangerously high |
Why do nmol/L and mg/dL results not convert?
The two units measure different things, so no fixed conversion factor exists between nmol/L and mg/dL. A result in mg/dL reports particle mass. A result in nmol/L reports particle count. Apolipoprotein(a) isoform size varies widely between people, so identical particle counts produce different masses depending on isoform. Laboratories and guideline committees now prefer nmol/L for this reason. Comparing a nmol/L result to an older mg/dL result introduces error.
What are the symptoms of high lipoprotein(a)?
High lipoprotein(a) produces no symptoms at all. No chest pain, no fatigue, no physical sign announces an elevated level. The first clinical evidence is frequently the cardiovascular event itself, which is precisely why the 2026 guideline moved to universal measurement rather than symptom-triggered testing.
Elevated lipoprotein(a) drives four specific conditions. Lipoprotein(a) accelerates coronary atherosclerosis and produces myocardial infarction. Lipoprotein(a) promotes arterial thrombosis and produces ischemic stroke. Lipoprotein(a) narrows peripheral arteries and produces peripheral artery disease. Lipoprotein(a) deposits within valve tissue and produces calcific aortic valve stenosis.
Imaging detects structural consequences once they form, which is the role a Bodyview: Full Body MRI Scan plays alongside blood-based risk markers.
How does lipoprotein(a) compare to LDL cholesterol and apolipoprotein B?
Lipoprotein(a), LDL cholesterol and apolipoprotein B measure three different things and answer three different questions. LDL cholesterol measures cholesterol mass. Apolipoprotein B counts atherogenic particles. Lipoprotein(a) measures one specific inherited particle type. None substitutes for another.
| Marker | What it measures | Genetically determined | Lowered by statins | On a standard lipid panel |
|---|---|---|---|---|
| Lipoprotein(a) | Concentration of Lp(a) particles carrying apolipoprotein(a) | More than 90% | No | No |
| LDL cholesterol | Cholesterol mass inside LDL particles | Partly | Yes, by 30% to 55% | Yes |
| Apolipoprotein B | Total count of atherogenic particles | Partly | Yes | No |
The 2026 ACC/AHA guideline assigns each marker a distinct job. Apolipoprotein B assesses residual risk in people who have already reached LDL cholesterol goals. Lipoprotein(a) identifies inherited risk the standard panel never captured, which is why a person at goal for LDL cholesterol still carries lipoprotein(a) risk nobody has measured.
How do you lower lipoprotein(a)?
No approved therapy lowers lipoprotein(a) specifically as of September 2026. Diet, exercise, weight loss and statins do not meaningfully reduce lipoprotein(a). Duarte Lau and Giugliano stated this directly in JAMA Cardiology in 2022, and the 2026 guideline repeats it. Three interventions remain available today.
No approved therapy lowers lipoprotein(a) specifically as of September 2026. Diet, exercise, weight loss and statins do not meaningfully reduce lipoprotein(a). Duarte Lau and Giugliano stated this directly in JAMA Cardiology in 2022, and the 2026 guideline repeats it.
Exercise still changes the rest of the risk picture. Training raises cardiorespiratory fitness, and a VO2 max chart scores that gain against people of the same age and sex. Three interventions remain available today.
- PCSK9 inhibitors such as evolocumab and alirocumab reduce lipoprotein(a) modestly, by roughly 20% to 25%, as a secondary effect of their LDL-lowering mechanism.
- Lipoprotein apheresis removes lipoprotein(a) mechanically from the blood, and remains reserved for people with very high levels and progressive disease.
- Intensified LDL cholesterol lowering is the guideline response to an elevated result, carrying a Class 1 recommendation, because reducing total atherogenic burden offsets part of the inherited lipoprotein(a) risk.
Five targeted drugs entered late-stage trials, and the first outcome result arrived recently. Novartis announced on September 4, 2026 that pelacarsen, a GalNAc-conjugated antisense oligonucleotide, lowered lipoprotein(a) substantially in the phase 3 Lp(a)HORIZON trial but did not meet its primary endpoint of reducing cardiovascular events. Bhatia, Bajaj, Goonewardena and Moriarty detailed the drug’s mechanism in the Journal of Clinical Lipidology in 2025.
Four programs continue: olpasiran in OCEAN(a)-Outcomes, lepodisiran in ACCLAIM-Lp(a), zerlasiran, and the oral small molecule muvalaplin in MOVE-Lp(a). Each lowers lipoprotein(a) by 85% or more. Lowering a biomarker is not the same as preventing an event, and the Lp(a)HORIZON result is the clearest demonstration of that distinction the field has produced.
Where can you get a lipoprotein(a) test in West Palm Beach?
A lipoprotein(a) test in West Palm Beach requires a provider who orders advanced lipid markers outside the routine annual panel. The Fountain operates at 1900 Okeechobee Blvd Ste A10, West Palm Beach, FL 33409, and works with patients on diagnostic testing that routine primary care visits leave out.
Andrei Gherghina, M.D., Medical Director at The Fountain, frames the gap this way: “A normal cholesterol panel reassures people who carry an inherited particle that panel never measured. Lipoprotein(a) is the clearest example. One blood draw answers a question a patient would otherwise carry for decades without knowing it existed.”
Patients weighing a single marker against broader assessment frequently start with a longevity blood test panel, which examines metabolic, inflammatory and cardiovascular markers together. The lipoprotein(a) result behaves differently from every other value there, because it holds steady year to year.
Frequently asked questions about the lipoprotein(a) test
Do you need to fast before a lipoprotein(a) test?
No. Lipoprotein(a) concentration does not shift with food intake, so the draw requires no fasting. Laboratories frequently run the lipoprotein(a) test alongside a fasting lipid panel for scheduling convenience rather than clinical necessity.
How much does a lipoprotein(a) test cost?
Cost varies by laboratory and by whether the lipoprotein(a) test is ordered alone or inside a wider panel. Request the cash price and the billing code from the ordering provider before the draw, because pricing is not standardized.
Does insurance cover a lipoprotein(a) test?
Coverage varies by plan. The Class 1 recommendation in the 2026 ACC/AHA guideline strengthens the case for coverage, though payer policies lag guideline updates. Verify benefits against diagnosis code E78.41, elevated lipoprotein(a), before testing.
How often should lipoprotein(a) be retested?
Once is enough for most adults. Lipoprotein(a) is genetically set and holds steady across life. Retesting applies in two situations: after starting a lipoprotein(a)-lowering therapy, and after a new kidney or thyroid diagnosis shifts the value.
Should children be tested if a parent has high lipoprotein(a)?
Cascade screening of first-degree relatives is standard practice once one family member tests high. The 2026 ACC/AHA guideline separately recommends universal lipid screening for children aged 9 to 11. Discuss timing with a pediatrician.
What does LPA mean on a lab report?
LPA on a lab report refers to lipoprotein(a), written variously as Lp(a) or LPA cholesterol. Laboratories abbreviate the marker inconsistently. The gene carrying those same three letters appears italicized as LPA in genetic reports.
Does lipoprotein(a) change with age or menopause?
Lipoprotein(a) holds broadly stable through adult life. Menopause raises lipoprotein(a) modestly in some women, and untreated hypothyroidism and kidney disease raise it as well. None of these shifts alters the underlying genetic setpoint.
Are there foods to avoid with high lipoprotein(a)?
No food meaningfully changes lipoprotein(a). Diet lowers LDL cholesterol and leaves lipoprotein(a) untouched. A person with high lipoprotein(a) still benefits from a heart-healthy diet, because that diet reduces the other risk factors stacked alongside it.
Can you live a long life with high lipoprotein(a)?
Yes. High lipoprotein(a) raises lifetime cardiovascular risk and does not determine the outcome. Controlling blood pressure, LDL cholesterol, blood sugar and smoking offsets a substantial share of the added risk that elevated lipoprotein(a) carries.
Is a lipoprotein(a) test the same as an LPA genetic test?
No. The lipoprotein(a) blood test measures the particle concentration circulating now. An LPA genotype test reads KIV-2 repeat number and variants within the gene. Clinical practice uses the blood concentration, not the genotype.
References
- Blumenthal, R. S., Morris, P. B., Gaudino, M., et al. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.
- Duarte Lau, F., & Giugliano, R. P. (2022). Lipoprotein(a) and its significance in cardiovascular disease: A review. JAMA Cardiology, 7(7), 760–769.
- Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., et al. (2022). Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(1), e48–e60.
- Berg, K. (1963). A new serum type system in man: The Lp system. Acta Pathologica et Microbiologica Scandinavica, 59(3), 369–382.
- Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014). Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. Journal of the American College of Cardiology, 63(5), 470–477.
- Koschinsky, M. L., & Boffa, M. B. (2022). Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis, 349, 92–100.
- Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., et al. (2025). 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 46(42), 4359–4378.
- Bhatia, H. S., Bajaj, A., Goonewardena, S. N., & Moriarty, P. M. (2025). Pelacarsen: Mechanism of action and Lp(a)-lowering effect. Journal of Clinical Lipidology, 19, 1208–1222.
- Novartis. (2026, September 4). Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease.
- Centers for Disease Control and Prevention. (2025). About lipoprotein (a). National Center for Chronic Disease Prevention and Health Promotion.
- Florida Department of Health. (2024). Deaths from heart diseases. FLHealthCHARTS, Division of Public Health Statistics and Performance Management.
